RCM
IGMS

RA Capital Management’s IGM Biosciences IGMS Stock Holding History

RA Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-937,500
Closed -$9.05M – 84
2024
Q1 		$9.05M Hold
937,500
– – 0.12% 72
2023
Q4 		$7.79M Hold
937,500
– – 0.12% 58
2023
Q3 		$7.83M Hold
937,500
– – 0.15% 58
2023
Q2 		$8.65M Buy
+937,500
New +$10.5M 0.16% 50
2021
Q2 		– Sell
-982,723
Closed -$75.4M – 94
2021
Q1 		$75.4M Hold
982,723
– – 1.14% 28
2020
Q4 		$86.8M Hold
982,723
– – 1.21% 25
2020
Q3 		$72.5M Hold
982,723
– – 1.33% 25
2020
Q2 		$71.7M Hold
982,723
– – 1.4% 24
2020
Q1 		$55.2M Hold
982,723
– – 1.74% 22
2019
Q4 		$37.5M Buy
982,723
+516,355
+111% +$13M 1.14% 22
2019
Q3 		$8.28M Buy
+466,368
New +$9.41M 0.49% 27

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RA Capital Management's IGMS Position: Q2 2024 in Review

RA Capital Management sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 937,500 shares — an estimated $9.05M sold.

RA Capital Management first reported a position in IGMS in Q3 2019 and held it in 11 quarters. The position peaked at $86.8M in Q4 2020. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

  • RA Capital Management reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
  • RA Capital Management sold 937,500 IGM Biosciences shares in Q2 2024, an estimated $9.05M.
  • RA Capital Management first reported a position in IGM Biosciences in Q3 2019 and held it in 11 quarters.
  • RA Capital Management's IGM Biosciences position peaked at $86.8M in Q4 2020.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.